Analyzing Healthcare M&A Trends: Q1 2024 Insights Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment. LEARN MORE
News Leerink Partners Adds Industry Veteran Andrew Gitkin to Healthcare Investment Banking Team April 2024
News Leerink Partners Strengthens Healthcare Services and Technology Team with Hire of Philip Boyd January 2024
